Rainier Therap 
Welcome,         Profile    Billing    Logout  
 1 Product   0 Diseases   1 Product   0 Trials   84 News 
  • ||||||||||  vofatamab (B-701) / Rainier Therap
    Journal:  Achieving a caregiver-friendly workplace standard for Canadian carer-workers: An ex ante evaluation of potential uptake. (Pubmed Central) -  Mar 16, 2025   
    With the assistance of a Committee of experts, McMaster University partnered with the Canadian Standards Association (CSA) to develop the Caregiver Inclusive and Accommodating Organizations Standard (B701-17)...Following transcription, interviews were thematically analyzed, resulting in four themes: (1) necessity; (2) impact of employer size; (3) motivators for implementation, and (4) use as an educational tool. Although initially in its early stages, the Standard now provides a key tool to improve accommodations for carer-workers.
  • ||||||||||  FPI-1966 / AstraZeneca
    Trial termination, Metastases:  A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours (clinicaltrials.gov) -  Dec 19, 2023   
    P1/2,  N=6, Terminated, 
    Although initially in its early stages, the Standard now provides a key tool to improve accommodations for carer-workers. Completed --> Terminated; Fusion announced that it is discontinuing this study as part of a portfolio prioritization and assessment; Fusion no longer plans to pursue development of FPI-1966.
  • ||||||||||  FPI-1966 / AstraZeneca
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours (clinicaltrials.gov) -  Oct 30, 2023   
    P1/2,  N=6, Completed, 
    Completed --> Terminated; Fusion announced that it is discontinuing this study as part of a portfolio prioritization and assessment; Fusion no longer plans to pursue development of FPI-1966. Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Sep 2023 | Trial primary completion date: Jun 2026 --> Sep 2023
  • ||||||||||  FPI-1966 / AstraZeneca
    Enrollment closed, Enrollment change, Metastases:  A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours (clinicaltrials.gov) -  May 12, 2023   
    P1/2,  N=6, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Sep 2023 | Trial primary completion date: Jun 2026 --> Sep 2023 Recruiting --> Active, not recruiting | N=155 --> 6
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    [VIRTUAL] MODULE 3: New Directions in the Management of UBC () -  Jun 5, 2021 - Abstract #ASCO2021ASCO_5875;    
    See Video Abstract at http://links.lww.com/DCR/B701. Available data from the Phase I/II CheckMate 032 trial of nivolumab alone or in combination with ipilimumab in the cohort of patients with advanced UBC Ongoing Phase III trials (eg, CheckMate 901, NILE) evaluating anti-PD-1/PD-L1 antibodies in combination with other systemic therapies as first-line therapy for patients with unresectable locally advanced or metastatic UBC Design, eligibility criteria and key endpoints of the ongoing Phase III PROOF 302 trial of the oral FGFR inhibitor infigratinib as adjuvant therapy for patients with MIBC harboring susceptible FGFR3 alterations Published research findings and ongoing evaluations of other FGFR-targeted agents (eg, pemigatinib, rogaratinib, vofatamab, LY3076226, futibatinib) in UBC Clinical rationale for the ongoing evaluation of enfortumab vedotin in combination with an immune checkpoint inhibitor as neoadjuvant therapy for cisplatin-eligible patients with MIBC (KEYNOTE-B15/EV-304) Potential role of the antibody-drug conjugate sacituzumab govitecan in heavily pretreated metastatic UBC Biologic rationale for the ongoing evaluations of the multi-receptor tyrosine kinase inhibitor cabozantinib in combination with one or more anti-PD-1/PD-L1 antibodies in UBC (eg, ABATE, ARCADIA, PemCab, ICONIC) Emerging targets (eg, ICOS, ATR) and other novel agents (eg, feladilimab, berzosertib) and strategies in clinical development for patients with UBC
  • ||||||||||  vofatamab (B-701) / Rainier Therap
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, PD(L)-1 Biomarker, Metastases:  FIERCE-22: A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (clinicaltrials.gov) -  Dec 11, 2019   
    P1b/2,  N=38, Terminated, 
    Available data from the Phase I/II CheckMate 032 trial of nivolumab alone or in combination with ipilimumab in the cohort of patients with advanced UBC Ongoing Phase III trials (eg, CheckMate 901, NILE) evaluating anti-PD-1/PD-L1 antibodies in combination with other systemic therapies as first-line therapy for patients with unresectable locally advanced or metastatic UBC Design, eligibility criteria and key endpoints of the ongoing Phase III PROOF 302 trial of the oral FGFR inhibitor infigratinib as adjuvant therapy for patients with MIBC harboring susceptible FGFR3 alterations Published research findings and ongoing evaluations of other FGFR-targeted agents (eg, pemigatinib, rogaratinib, vofatamab, LY3076226, futibatinib) in UBC Clinical rationale for the ongoing evaluation of enfortumab vedotin in combination with an immune checkpoint inhibitor as neoadjuvant therapy for cisplatin-eligible patients with MIBC (KEYNOTE-B15/EV-304) Potential role of the antibody-drug conjugate sacituzumab govitecan in heavily pretreated metastatic UBC Biologic rationale for the ongoing evaluations of the multi-receptor tyrosine kinase inhibitor cabozantinib in combination with one or more anti-PD-1/PD-L1 antibodies in UBC (eg, ABATE, ARCADIA, PemCab, ICONIC) Emerging targets (eg, ICOS, ATR) and other novel agents (eg, feladilimab, berzosertib) and strategies in clinical development for patients with UBC N=74 --> 38 | Trial completion date: Sep 2022 --> Dec 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2021 --> Dec 2019; program has been put on hold by the sponsor
  • ||||||||||  Review, Journal:  Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. (Pubmed Central) -  Dec 8, 2019   
    The Food and Drug Administration recently granted accelerated approval to erdafitinib for patients with advanced UC with alterations of FGFR2 or FGFR3 after progression on platinum-based chemotherapy. We also look at future therapeutic options of combination regimens with immune-checkpoint inhibitors as strategies for improving the antitumor effects of this class of drug, and for preventing or delaying the development of resistance.
  • ||||||||||  vofatamab (B-701) / Rainier Therap
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases:  FIERCE 21: Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (clinicaltrials.gov) -  Nov 18, 2019   
    P1/2,  N=70, Terminated, 
    We also look at future therapeutic options of combination regimens with immune-checkpoint inhibitors as strategies for improving the antitumor effects of this class of drug, and for preventing or delaying the development of resistance. N=300 --> 70 | Trial completion date: Dec 2021 --> Nov 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2021 --> Nov 2019; program has been put on hold by the sponsor
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), vofatamab (B-701) / Rainier Therap
    Enrollment change, Trial termination, Trial primary completion date, Metastases:  Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract (clinicaltrials.gov) -  Jun 27, 2017   
    P1b,  N=1, Terminated, 
    Trial primary completion date: Sep 2018 --> Dec 2018 N=12 --> 1 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Jun 2017; Terminated due to safety concerns.